Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study

Annals of Oncology

Volumn 9, Issue 11, 1998, Pages 1193-1198

  Vansteenkiste, J F ^a   Stroobants, S G ^a   De Leyn, P R ^a   Dupont, P J ^a   Verbeken, E K ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Combined modality treatment; Emission computed tomography; Lymphatic metastasis; Non small cell lung carcinoma; Outcome assessment; Staging lung neoplasms; X ray computed tomography

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; VINDESINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031772968     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008437915860     Document Type: Article

References (35)

1. 2 non-small-cell lung cancer: A study of 140 cases. The Leuven Lung Cancer Group. Ann Thorac Surg 1997; 63: 1441-50.
2. 2 lung cancer. Surg Clin North Am 1987; 67: 1037-49.
3. Pearson F, DeLarue N, lives R et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982; 83: 1 11.
4. Johnson DH, Einhorn LH, Bartolucci A et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unreseciable non-small-cell lung cancer. Ann Intern Med 1990; 113: 33-8.
5. 2). Cancer 1996; 77: 2393-9.
6. Arriagada R. Optimizing chemotherapy and radiotherapy in locally advanced non-small-cell lung cancer. Hematol Oncol Clin North Am 1997; 11:461-72.
7. 2 non-small-cell lung cancer: A review. Eur J Cardiothorac Surg 1998; 13: 1-12.
8. 2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-74.
9. 2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-92.
10. Rice TW, Adclstein DJ, Koka A et al. Accelerated induction therapy and resection for poor prognosis stage III non-small-cell lung cancer. Ann Thorac Surg 1995; 60: 586-91.
11. Weilberg AB, Yashar J, Glicksman AS et al. Combined modality therapy for stage IIIA non-small-cell carcinoma of the lung. Eur J Cancer 1993; 29A: 511-5.
12. Strauss GM, Herndon JE, Sherman DD et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10: 1237-44.
13. Choi NC, Carey RW, Daly W et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997; 15: 712-22.
14. Pisters KM, Kris MG, Gralla RJ et al. Pathologic complete response in advanced non-small-cell-lung cancer following preoperative chemotherapy: Implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993; 11: 1757-62.
15. Vansteenkiste JF, Stroobants SG, De Leyn PR et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small-cell lung cancer: A prospective analysis of 50 cases. Chest 1997; 112: 1480-6.
16. Vansteenkiste JF, Stroobants SG, De Leyn PR et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16: 2142-9.
17. Woodard HQ, Bigler RE, Freed B, Russ G. Expression of tissue isotope distribution. J Nucl Med 1975; 16: 958-9.
18. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Surg 1978; 76: 832-7.
19. 2 non-small-cell lung cancer: A prospective study. Ann Oncol 1998; 9: 261-7.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
21. Maes F, Collignon A, Vandermeulen D et al. Multi-modality image registration by maximization of mutual information. IEEE Trans Med Imag 1997; 16: 186-97.
22. Bury T, Dowlati A, Paulus P et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. EurRespir J 1996; 9: 410-4.
23. Patz EF, Lowe VJ, Hoffman JM et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90.
24. Dewan NA, Rceb SD, Gupta NK et al. PET-FDG imaging and transthoracic needle aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995; 108: 441-6.
25. Lowe VJ, Duhaylongsod FG, Patz EF et al. Pulmonary abnormalities and PET data analysis: A retrospective study. Radiology 1997; 202: 435-9.
26. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-6.
27. Steinert HC, Hauser M, Allemann F et al. Non-small-cell lung cancer: Nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-6.
28. Strauss LG. Positron emission tomography: Current role for diagnosis and therapy monitoring in oncology Oncologist 1997; 2: 381-8.
29. Kubota K, Yamada S, Ishiwata K et al. Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-IIC]methionine: A preliminary study. Eur J Nucl Med 1993; 20: 495-501.
30. Hebert ME, Lowe VJ, Hoffman JM et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small-cell lung cancer patients treated with radiotherapy: Preliminary findings. Am J Clin Oncol 1996; 19: 416-21.
31. Ichiya Y, Kuwabara Y, Sasaki M et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996; 10: 193-200.
32. Pastorino U, Andreola S, Tagliabue E et al. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 1997; 15: 2858-65.
33. Haberkorn U, Strauss LG, Reisser C et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32: 1548-55.
34. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: A method to assess the proliferate activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-81.
35. Miyazawa H, Arai T, Iio M, Hara T, PET imaging of non-small-cell lung carcinoma with carbon-II-methionine: Relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993; 34: 1886-91.